## UNITED STATES SECURITIES AND EXCHANGE COMMISSION March 19, 2019

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

## Ionis Pharmaceuticals, Inc.

File No. 0-19125 - CF#37298

Ionis Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 1, 2019.

Based on representations by Ionis Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.67	through October 9, 2028
Exhibit 10.68	through October 20, 2027
Exhibit 10.69	through July 31, 2025
Exhibit 10.70	through July 31, 2025

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Vanessa Countryman Acting Secretary